NK
NKGN.US NKGen Biotech, Inc. Common Stock
- Market cap
- USD 7.84M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is NKGN.US undervalued?
Graham numberThe Graham number of NKGen Biotech, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NKGen Biotech, Inc. Common Stock fundamental analysis
No fundamental analysis for NKGen Biotech, Inc. Common Stock yet.
NKGen Biotech, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NKGen Biotech, Inc. Common Stock
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed P…
Full company profileNKGen Biotech, Inc. Common Stock financial statements
NKGen Biotech, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 426K | 77.0K | 0.00 | - |
| Gross Profit | 396K | 59.0K | -1.20M | - |
| Operating Income | -21.9M | -24.3M | -29.7M | -27.0M |
| EBITDA | -20.7M | -23.2M | -81.0M | -40.2M |
| Net Income | -23.3M | -26.8M | -83.0M | -44.3M |
| EPS | -1.08 | -1.25 | -5.38 | -1.54 |
| Balance Sheet | ||||
| Total Assets | 18.1M | 16.3M | 16.5M | 24.0K |
| Total Liabilities | 56.1M | 14.8M | 75.2M | - |
| Shareholders' Equity | -38.1M | 1.56M | -58.7M | - |
| Cash & Short-term Investments | 351K | 117K | 26.0K | - |
| Total Debt | 52.0M | 12.0M | 19.9M | - |
| Cash Flow | ||||
| Operating Cash Flow | -19.5M | -22.6M | -21.9M | -20.9M |
| Capital Expenditure | 459K | 163K | 48.0K | 0.00 |
| Free Cash Flow | -20.0M | -22.7M | -22.0M | -20.9M |
| Ratios | ||||
| ROE | - | -1,711.7% | - | - |
| ROA | -128.7% | -163.8% | -503.3% | -184,525.0% |
| Net Profit Margin | -5,461.3% | -34,745.5% | - | - |
| Debt to Equity | - | 7.70x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
NKGen Biotech, Inc. Common Stock dividends
NKGen Biotech, Inc. Common Stock has not paid dividends in the last 4 fiscal years.
Who owns NKGen Biotech, Inc. Common Stock
- Insiders 58.97%
- Institutions 2.11%
- Public & others 38.92%
- Shares outstanding 131M
- Free float 67.6M
NKGen Biotech, Inc. Common Stock company profile
- Company name
- NKGen Biotech, Inc. Common Stock
- Ticker
- NKGN.US
- Exchange
- USA Stocks
- Listed since
- Jul 13, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 26
- Fiscal year end
- December
- Address
- 3001 Daimler Street, Santa Ana, CA, United States, 92705
- Phone
- 949 396 6830
- Website
- nkgenbiotech.com
About NKGen Biotech, Inc. Common Stock
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HER2-CAR NK cell therapy candidate in pre-clinical trial to treat refractory solid tumors. It has a strategic partnership with HekaBio K.K., a Japan-based healthcare platform, to develop, conduct clinical trials, obtain regulatory approvals, manufacture, and commercialize the company's autologous NK cell therapy product candidates for central nervous system and autoimmune conditions in Japan. The company also has a license agreement with NKMAX Co., Ltd. for the research and development of its NK cell program. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
NKGen Biotech, Inc. Common Stock management
7- Dr. Paul Y. Song M.D.CEO & Chairman · born 1966
- Mr. James A. GrafInterim Chief Financial Officer · born 1965
- Ms. Yoonmi KangSVP of Technical Ops & Development
- Dr. Yong Man Kim Ph.D.Chief Scientific Officer · born 1965
- Ms. Irene ChangSVP, HR & Corporate Culture
- Ms. Denise A. Chua CLS, MBA, MT (ASCP)SVP of Corporate Affairs
- Mr. Ryan Park C.F.A.EVP of FP&A, Corporate Planning & Strategy